Generalizing the TITE-CRM to adapt for early- and late-onset toxicities

Statistics in Medicine

Volumn 25, Issue 12, 2006, Pages 2071-2083

  Braun, Thomas M ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE   (United States)

Author keywords

Bayesian statistics; CRM; Cure model; Dose escalation trial; Mixture model; Phase I trial

Indexed keywords

DRUG;

ACUTE TOXICITY; ALGORITHM; ARTICLE; BAYES THEOREM; BINOMIAL DISTRIBUTION; BIOSTATISTICS; CHRONIC TOXICITY; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONTE CARLO METHOD; PROBABILITY; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; SURVIVAL; TIME SERIES ANALYSIS; TIME TO EVENT CONTINUAL REASSESSMENT METHOD; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; TIME FACTORS;

EID: 33745473565     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2337     Document Type: Article

References (10)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
2. Goodman S, Zahurak M, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14:1149-1161.
3. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics 1996; 52:673-684.
4. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1998; 17:1103-1120.
5. Gasparini M, Eisele J. A curve-free method for phase I clinical trials. Biometrics 2000; 56:609-615.
6. Leung DHY, Wang YG. Isotonic designs for phase I trials. Controlled Clinical Trials 2001; 22:126-138.
7. Cheung Y, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000; 56:1177-1182.
8. Berkson J, Gage R. Survival curves for cancer patients following treatment. Journal of the American Statistical Association 1952; 47:510-515.
9. Farewell V. The use of mixture models for the analysis of survival data with long-term survivors. Biometrics 1982; 38:1041-1046.
10. Thall PF, Russell KT. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 1998; 54:251-264.